TriNetX, the global health research network for healthcare organizations, biopharmaceutical companies, and Contract Research Organizations (CROs) has announced their collaboration with their client, Tufts Medical Center, a not-for-profit, 415-bed academic medical center that is home to both a full-service hospital for adults and Floating Hospital for Children, bringing an additional one million patients to the global health research network.
Network members utilize TriNetX’s cloud-based, health research platform to analyze patient populations and perform “what-if” analyses in real-time. As members, healthcare organizations receive hardware and software that are configured within the organization’s IT infrastructure and often builds on existing data resources such as Observational Medical Outcomes Partnership (OMOP) and i2b2. Researchers then have access to the institution’s de-identified patient data through a user-friendly interface and a growing number of visualization and analysis capabilities.
Increasingly, technology has become instrumental in fostering a powerful data-driven approach to clinical research, and as Boston continues to gain recognition for being at the forefront of biotech globally, collaborations like this one and others recently announced exemplify how TriNetX is leading this growth. In the last quarter, top healthcare organizations such as Boston Children’s Hospital, USC Keck, and Weill Cornell Medicine have integrated TriNetX, further impacting the trend in healthcare of accessing a wider pool of patient data in an effort to accelerate the study start-up process and identification of patients for clinical trials. Additionally, TriNetX has announced pharmaceutical partnerships with the likes of Sanofi and Pfizer.
“We look forward to using TriNetX’s query and analytics capabilities to dig deeper into our clinical data both to recruit eligible patients into clinical trials and to generate new hypotheses for investigation,” said Dr. Harvey. “Additionally, we hope to attract more sponsored research studies that seek to take advantage of our unique patient populations.”